Well before the modern WHO histological classification of lung cancer it was accepted that inoperable cancers sometimes responded dramatically to radiotherapy, occasionally resulting in a cure.' 2 It also became clear at much the same time that the pattern of response and relapse in small cell lung cancer was quite different from other types, with a more rapidly evolving pattern of metastatic disease and, most importantly, a greater degree of radiosensitivity. 3 Before the advent of combination chemotherapy as standard treatment for small cell lung cancer, radiotherapy was widely used. Fletcher, in the first edition (1966) of a classic radiotherapy text,4 noted that "undifferentiated carcinoma responds to radiation better than squamous cell carcinoma." Indeed it was only 30 years ago (1962) that the MRC designed a prospectively randomised study5 to compare radiotherapy and surgical resection for limited small cell lung cancer, an unusually far sighted initiative at the time. The study was finally launched in 1964 and showed unequivocally, and for the first time, the superiority of non-surgical treatment. 6 The rapid establishment of combination chemotherapy as the standard approach for both limited and extensive small cell lung cancer was largely the result of further MRC studies in the UK, together with supporting evidence from the USA and Europe,78 although the early promise of combination chemotherapy proved difficult to sustain in the long term. The promising early results from combination chemotherapy in small cell lung c-ancer led many groups to abandon thoracic irradiation as "illogical" in a disease which was frequently systemic, even at presentation, and led to heated debate in the mid 1980s as to the value of thoracic radiotherapy as "consolidation" in patients now routinely treated with aggressive combination chemotherapy." 12 As Cohen" pointed out in marshalling arguments against thoracic radiotherapy, "combination chemotherapy can achieve similar therapeutic results... and generally produces less severe toxicity (than radiotherapy)... combined modality treatment may result in debilitating chronic toxicity, and long term chemotherapy toxicity is qualitatively and quantitatively less severe." He pointed out correctly that long term local control required a high dose of thoracic radiotherapy (greater than 50 Gy with conventional fractionation) despite the relative radiosensitivity of the lesion, and also that significant acute toxic effects occur with combined modality treatment. Apart from the acute side effects, patients treated with combined chemotherapy + radiotherapy are clearly at risk of long term respiratory impairment from pulmonary/mediastinal fibrosis, oesophagitis and oesophageal stricture and, occasionally, significant radiation myelopathy. In addition, in patients with breast cancer-a group with a large well documented cohort of survivors (unlike small cell lung cancer) for study-thoracic irradiation also appears to produce significant myocardial ischaemia. By analogy this might also represent a major hazard in the small number of long term survivors of small cell lung cancer since a substantial portion of the myocardium is inevitably irradiated.
How to resolve these difficult issues? Although this was not a very substantial numerical difference, the major conclusion was that there was indeed a small but statistically significant advantage for patients treated with the chemotherapy + radiotherapy combination, with a final point estimate of benefit clearly on the "treatment better" side of the isoeffect line and with confidence limits which did not cross into the "no benefit" area. The pooled relative risk from the analysis was 0-82, corresponding to an 18% reduction in the risk of death from disease.
A further interesting trend emerged in that subgroup analysis showed a clear correlation between the degree of benefit obtained from thoracic radiotherapy and the age of the patient treated. Younger patients had more to gain, with a relative reduction in the risk of death in younger patients (under 55 years) of 0-72-that is, a 28%
reduction from the addition of radiotherapy to combination chemotherapy. In these patients the three year survival rates were 9-2% with chemotherapy alone and a dramatically better 17-4% with the chemotherapy + radiotherapy combination. In patients over the age of 70 years the rates were similar: 10-2% and 8-7% were lost to follow up after three years and a further criticism of the study-as the authors themselves recognised-was the failure to evaluate non-lethal toxicity of treatment, making it impossible to apply a "cost-benefit" or "tradeoff' analysis against the potential advantage in longevity.
It seems unlikely that we will ever gain a clearer view of the potential benefit from thoracic radiotherapy in patients with limited small cell lung cancer since many have already concluded that the advantages of radiotherapy are now clear cut. In a disease with such high mortality, potential long term disadvantages of treatment are unlikely to weigh heavily, given the degree of additional benefit, particularly in patients under the age of 55 years.
Important further questions still remain, however. What, for example, is the optimal schedule of treatment? Do we need to push the radiotherapy dose still higher? Is there a real difference between "early" and "late" thoracic radiotherapy in terms of treatment benefit, as recently suggested' by Murray and others'6 in a most important randomised study?
There are certainly theoretical reasons to favour early radiotherapy and concurrent or alternating chemotherapy regimens'7 and future studies need to address this issue. Recent data from NCI, Canada suggest a substantial benefit from the early use of radiotherapy-that is, given concurrently with the first course of chemotherapy. '6 In these patients the median survival was 21 2 months compared with only 16 months for patients treated by "delayed" radiotherapy (given at week 15 with the final cycle of chemotherapy). It 
